2020
Lifting the innate immune barriers to antitumor immunity
Rothlin CV, Ghosh S. Lifting the innate immune barriers to antitumor immunity. Journal For ImmunoTherapy Of Cancer 2020, 8: e000695. PMID: 32273348, PMCID: PMC7254113, DOI: 10.1136/jitc-2020-000695.BooksConceptsImmune responseImmune systemInnate immunityT-cell checkpoint inhibitorsMyeloid-derived suppressor cellsInnate immune cell functionBenefit of immunotherapyNatural killer cellsT cell activityInnate immune barrierInnate immune cellsT cell checkpointAnticancer immune responseAdaptive immune responsesImmune cell functionActivated T cellsAnticancer treatment modalitiesLarger patient poolCheckpoint inhibitorsAntitumor immunitySuppressor cellsDendritic cellsPD-L1Exaggerated inflammationKiller cells
2014
Tyro3, Axl, and Mertk Receptor Signaling in Inflammatory Bowel Disease and Colitis-associated Cancer
Rothlin CV, Leighton JA, Ghosh S. Tyro3, Axl, and Mertk Receptor Signaling in Inflammatory Bowel Disease and Colitis-associated Cancer. Inflammatory Bowel Diseases 2014, 20: 1472-1480. PMID: 24846720, PMCID: PMC4343000, DOI: 10.1097/mib.0000000000000050.BooksConceptsInflammatory bowel diseaseBowel diseaseImmune responseT-cell-dependent adaptive immune responsesApoptotic cellsReceptor tyrosine kinasesProinflammatory cytokine productionSuppression of inflammationAdaptive immune responsesInnate immune responseTAM receptor tyrosine kinasesPotent therapeutic opportunityDisease remissionTyrosine kinaseIntestinal inflammationCytokine productionInflammatory responseLigand Gas6Potent negative regulatorTherapeutic opportunitiesGenetic ablationInflammationProtein SReceptor signalingSuccessful management